---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-118940"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2022-04-26T23:59:59+00:00"
generated_at: "2026-06-26T04:44:02.905173+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharmaceuticals appoints Frank Karbe to board of directors

## Summary
- Frank Karbe appointed as Class II director effective April 25, 2022; will serve on audit and compensation committees.
- Karbe previously served as President and CFO of Myovant Sciences, and EVP and CFO of Exelixis.
- Received option to purchase 20,000 shares of common stock with three-year vesting, plus cash compensation.

## SEC filing metadata
- accession: 0001193125-22-118940
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2022-04-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/0001193125-22-118940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/d622345d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-118940
- JSON: https://secwatch.observer/filing/0001193125-22-118940.json
- Plain text: https://secwatch.observer/filing/0001193125-22-118940.txt

## Key facts
- Executive change
  Frank Karbe was appointed as Director at Phathom Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On April 25, 2022, the board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Frank Karbe to the Board as a Class II director, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/0001193125-22-118940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.